Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSJ2I6)

Drug Name
Beta-aminopropionitrile Drug Info
Synonyms
3-aminopropionitrile; 3-Aminopropanenitrile; 151-18-8; 2-Cyanoethylamine; Aminopropionitrile; BETA-AMINOPROPIONITRILE; Propanenitrile, 3-amino-; BAPN; 3-Aminopropiononitrile; beta-Cyanoethylamine; beta-Alaninenitrile; Propionitrile, 3-amino-; beta-Aminoethyl cyanide; beta-Alaminenitrile; UNII-38D5LJ4KH2; NSC 40641; 3-amino-propionitrile; beta-Alaninenitrile; CHEBI:27413; beta-Cyanoethylamine; beta-Aminopropionitrile; H2NCH2CH2CN; MFCD00014820; 38D5LJ4KH2; CHEMBL1618272; 3-Aminopropionitrile, 98%, stabilized; 3-Aminopropionitrile; Aminopropionitrile; BAPN; N-(2-Cyanoethyl)amine; NSC 40641; HSDB 2897; EINECS 205-786-0; BRN 1698848; cyanoethylamine; aminoethylcyanide; b-Alaminenitrile; b-Alaninenitrile; CCRIS 8134; b-Cyanoethylamine; 3-Aminopropanitrile; EINECS 268-598-8; b-Aminoethyl cyanide; 3-aminopropanonitrile; Propanenitrile, 3-amino-, N-C11-13-isoalkyl derivs.; n-(2-cyanoethyl)amine; PubChem19134; beta-amino propionitrile; beta-amino-propionitrile; (C12-C18)Alkyl alkoxyethyleneaminonitrile; Lopac-A-3134; beta-Aminoethyl cyanide; (C11-C13)Branched alkyl aminoethylenenitrile; WLN: Z2CN; ACMC-1B8B9; Lopac0_000055; 68130-65-4; 68130-66-5; C(#N)CC[N]; DTXSID6048418; AGSPXMVUFBBBMO-UHFFFAOYSA-; 3-amino-propionitrile, AldrichCPR; SODIUMBITARTRATE,MONOHYDRATE; CS-D1507; HY-Y1750; NSC40641; STR02529; ZINC1530259; ANW-43145; BBL101609; BDBM50232678; NSC-40641; Propanenitrile, 3-amino-, N-(3-(C12-18-alkyloxy)propyl) derivs.; STL555405; AKOS000121388; NCGC00015048-01; NCGC00015048-02; NCGC00015048-03; NCGC00015048-05; NCGC00162054-01; 3-Aminopropionitrile stabilized with K2CO3; A0408; FT-0615060; C05670; 97104-EP2298731A1; 97104-EP2305660A1; Q3614347; W-109080
Indication
Disease Entry ICD 11 Status REF
Cardiac arrest MC82 Preclinical [1]
Cross-matching ID
PubChem CID
1647
ChEBI ID
CHEMBL27413
CAS Number
CAS 151-18-8
TTD Drug ID
DMSJ2I6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Lysyl oxidase homolog 2 (LOXL2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GS-6624 DMV7ZU0 Colorectal cancer 2B91.Z Phase 2 [4]
Drug(s) Affected By Protein-lysine 6-oxidase (LOX)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [5]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [6]
Quercetin DM3NC4M Obesity 5B81 Approved [7]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [8]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [9]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [10]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [11]
Ethanol DMDRQZU Chronic pain MG30 Approved [12]
Ampicillin DMHWE7P Acute epiglottitis Approved [7]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lysyl oxidase homolog 2 (LOXL2) TTFSUHX LOXL2_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Protein-lysine 6-oxidase (LOX) OT1C2HIU LYOX_HUMAN Gene/Protein Processing [3]

References

1 Drugs and Targets in Fibrosis. Front Pharmacol. 2017 Nov 23;8:855.
2 Wnt signaling and Loxl2 promote aggressive osteosarcoma. Cell Res. 2020 Oct;30(10):885-901.
3 Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol. 2005 Sep;43(3):499-507. doi: 10.1016/j.jhep.2005.02.052.
4 National Cancer Institute Drug Dictionary (drug id 681814).
5 Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
6 NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer. 2009 Jan 1;124(1):223-32. doi: 10.1002/ijc.23934.
7 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
8 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
9 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
10 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
11 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
12 Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
13 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.